Cochrane · systematic review · CD011673
Immunotherapy for metastatic renal cell carcinoma
Unverzagt, S, Moldenhauer, I, Nothacker, M, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
19
No studies
4
Included studies
NR
No studies 4 · 17.4%Ungraded 0 · 0%Very low 0 · 0%Low 12 · 52.2%Moderate 7 · 30.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Interferon‐α alone versus standard targeted therapies (sunitinib or temsirolimus) in first‐line therapy of metastatic renal cell carcinoma
Population: previously untreated patients with mRCC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
1‐year mortality Interferon‐α alone vs standard targeted therapies (sunitinib or temsirolimus) | RR 1.3 [1.13, 1.51] | 2 studies · 1166 participants | Moderate Downgraded: risk of bias |
QoL FACT‐G Interferon‐α alone vs standard targeted therapies (sunitinib or temsirolimus) | no estimate extracted | 1 study · 730 participants | Low Downgraded: risk of bias, imprecision |
QoL FKSI‐15 Interferon‐α alone vs standard targeted therapies (sunitinib or temsirolimus) | no estimate extracted | 1 study · 730 participants | Low Downgraded: risk of bias, imprecision |
QoL FKSI‐DRS Interferon‐α alone vs standard targeted therapies (sunitinib or temsirolimus) | no estimate extracted | 1 study · 730 participants | Low Downgraded: risk of bias, imprecision |
QoL EQ‐5D Interferon‐α alone vs standard targeted therapies (sunitinib or temsirolimus) | no estimate extracted | 2 studies · 1002 participants | Low Downgraded: risk of bias, imprecision |
QoL EQ‐VAS Interferon‐α alone vs standard targeted therapies (sunitinib or temsirolimus) | no estimate extracted | 2 studies · 1002 participants | Low Downgraded: risk of bias, imprecision |
Adverse events (grade ≥ 3) Interferon‐α alone vs standard targeted therapies (sunitinib or temsirolimus) | RR 1.17 [1.03, 1.32] | 1 study · 408 participants | Low Downgraded: risk of bias, imprecision |
Interferon‐α combined with targeted therapies versus standard targeted therapy in first‐line therapy of metastatic renal cell carcinoma
Population: previously untreated patients with mRCC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
1‐year mortality Interferon‐α combined with targeted therapies vs standard targeted therapy | RR 1.13 [0.95, 1.34] | 1 study · 419 participants | Moderate Downgraded: imprecision |
Quality of life Interferon‐α combined with targeted therapies vs standard targeted therapy | no estimate extracted | NR | No studies |
Adverse events (grade ≥ 3) Interferon‐α combined with targeted therapies vs standard targeted therapy | RR 1.3 [1.17, 1.45] | 1 study · 416 participants | Low Downgraded: risk of bias, imprecision |
Interferon‐α alone versus interferon‐α plus bevacizumab in first‐line therapy of metastatic renal cell carcinoma
Population: previously untreated patient with mRCC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
1‐year mortality Interferon‐α alone vs interferon‐α plus bevacizumab | RR 1.17 [1, 1.36] | 2 studies · 1381 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Interferon‐α alone vs interferon‐α plus bevacizumab | no estimate extracted | NR | No studies |
Adverse events (grade ≥ 3) Interferon‐α alone vs interferon‐α plus bevacizumab | RR 0.77 [0.71, 0.84] | 2 studies · 1350 participants | Moderate Downgraded: risk of bias |
Interferon‐α plus bevacizumab versus standard targeted therapies in first‐line therapy of metastatic renal cell carcinoma
Population: previously untreated patients with mRCC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
1‐year mortality median Interferon‐α plus bevacizumab vs standard targeted therapies | RR 0.37 [0.13, 1.08] | 1 study · 83 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Interferon‐α plus bevacizumab vs standard targeted therapies | no estimate extracted | NR | No studies |
Adverse events (grade ≥ 3) Interferon‐α plus bevacizumab vs standard targeted therapies | RR 1.18 [0.85, 1.62] | 1 study · 82 participants | Low Downgraded: risk of bias, imprecision |
Vaccine treatment versus standard therapies in first‐line therapy of metastatic renal cell carcinoma
Population: previously untreated patients with mRCC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
1‐year mortality Vaccine treatment vs standard therapies | RR 1.1 [0.91, 1.32] | 2 studies · 1034 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Quality of life Vaccine treatment vs standard therapies | no estimate extracted | NR | No studies |
Adverse events (grade ≥ 3) Vaccine treatment vs standard therapies | RR 1.16 [0.97, 1.39] | 2 studies · 1065 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Targeted immunotherapy alone versus standard targeted therapies in previously treated patients with metastatic renal cell carcinoma
Population: previously treated patients with mRCC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
1‐year mortality Targeted immunotherapy alone vs standard targeted therapies | RR 0.7 [0.56, 0.87] | 1 study · 821 participants | Moderate Downgraded: risk of bias |
Quality of life: Clinically relevant improvement in FKSI‐DRS Targeted immunotherapy alone vs standard targeted therapies | RR 1.51 [1.28, 1.78] | 1 study · 704 participants | Moderate Downgraded: risk of bias |
Quality of life: clinically relevant improvement in EQ‐5D VAS Targeted immunotherapy alone vs standard targeted therapies | RR 1.37 | 1 study · 703 participants | Moderate Downgraded: risk of bias |
Adverse events (grade ≥ 3) Targeted immunotherapy alone vs standard targeted therapies | RR 0.51 [0.4, 0.65] | 1 study · 803 participants | Moderate Downgraded: risk of bias |